

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



July 21, 2023

Update to Pfizer Hospital U.S. Customers on the Impact of the Rocky Mount Tornado

Dear Customer,

Our Pfizer Rocky Mount, North Carolina, manufacturing facility was damaged by a tornado on July 19, 2023. Fortunately, all our colleagues are safe and accounted for. The Rocky Mount, North Carolina site is one of the largest sterile injectable facilities in the world, with more than 1.4 million square feet of manufacturing space on 250 acres of land in Eastern North Carolina. The facility produces a wide range of products that are available in small volume presentations, such as ampules, vials, and syringes.

We understand our customers have questions and may be concerned about the potential impact to supply and continuity of patient care. Consistent with our ongoing efforts to provide timely and transparent supply updates to our U.S. customers—and understanding the importance of our Rocky Mount products to patients and health care professionals—we are sharing the following preliminary updates now, with the commitment to communicate additional specifics to customers as soon as possible.

Please note the following information regarding production impact:

- After an initial assessment, there does not appear to be any major damage to the production areas.
- Most of the damage was caused to the warehouse facility, which stores raw materials, packaging supplies, and finished medicines awaiting release by quality assurance.
- The site is closed while the damage is assessed. Crews are working around-the-clock to restore power, assess the structural integrity of the buildings and move finished medicines to nearby sites for storage and to identify sources to replace damaged raw materials and supplies.
- We are working urgently to restart production, but do not currently have an estimated date at which this will occur. We will continue to keep customers apprised as we learn more.
- We are also exploring alternative manufacturing locations for production across our significant manufacturing presence in the U.S. and internationally and across the company's partner network.

Please note the following information related to potential supply disruptions:

- In order to provide customers with the ability to plan for patient care today, we have identified a subset of Rocky Mount products by NDC that may experience continued or new supply disruptions in the near-term due to this weather event. This subset is based on Pfizer market share and inventory levels of less than 3 months across our Pfizer distribution centers and the wholesale chain. Note that the 3-month inventory threshold represents an abundance of caution based on the information available today and is not reflective of any estimates of production restart.

- As we learn more from the site assessment and estimated production restart dates, we will refine this information and provide additional updates.

Please note the following information regarding available inventory in the distribution chain:

- Pfizer Hospital will continue to fill orders of products for which we have inventory in the distribution chain at 100 percent of historical levels.
- As we learn more from the site assessment and estimated production restart dates, we will make necessary adjustments and provide timely updates.
- Out of an abundance of caution due to the weather event, we recently placed allocations on the entire Pfizer Hospital portfolio. The allocations on non-Rocky Mount products will be lifted.
- Please note that any products that were in limited supply status prior to the weather incident may still have allocations in place that are independent of the Rocky Mount situation.
- At this time, our [Availability Report](#) on www.PfizerHospitalUS.com has not yet been updated to reflect the impact of the Rocky Mount tornado. Please refer to the guidance in this letter until further notice.
- Please note that Pfizer does not produce COMIRNATY® (COVID-19 Vaccine, mRNA), or PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) at the site. We also do not produce sterile injectable oncology products, SOLU-CORTEF® (hydrocortisone sodium succinate for injection, USP), SOLU-MEDROL® (methylprednisolone sodium succinate for injection, USP), or BICILLIN® L-A (penicillin G benzathine injectable suspension) at the site.

Pfizer is working closely with the FDA and other regulatory bodies and will continue to share information as it becomes available. In the meantime, for product availability questions, please reach out to your Pfizer Hospital sales representative or account executive. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 5 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

We appreciate the outpouring of cooperation and assistance from local, state, and federal governments, as well as our customers' concerns for the wellbeing of our colleagues at the Rocky Mount site. As we do our best to minimize disruption to patient care, please keep our colleagues and the community in mind as we rebuild from this weather incident.

These critical medicines are of great importance for patients, and we are committed to recovering our supply as soon as possible. We appreciate your patience and partnership during this time.

Thank you,

Meera Bhavsar
Sterile Injectables Portfolio Lead
Pfizer Hospital U.S.

**APPENDIX:
Pfizer Hospital Rocky Mount Products with Less Than 3 Months' Inventory in the Distribution Chain**

| NDC | Product Description |
|---------------|---|
| 00409-3308-03 | Acetylcysteine Solution, USP 6 g/30 mL (200 mg/mL) Multiple Dose Glass Teartop Vial |
| 00409-4346-73 | Aminocaproic Acid Injection, USP 5 g/20 mL (250 mg/mL) Single Dose Plastic Fliptop Vial |
| 00409-5921-01 | Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1630-10 | Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) ANSYR™ Plastic Syringe |
| 00409-4911-34 | Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") |
| 00409-1966-12 | Bacteriostatic 0.9% Sodium Chloride Injection, USP 10 mL Multiple Dose LifeShield™ Plastic Fliptop Vial |
| 00409-3613-01 | Bupivacaine 0.75% Spinal (bupivacaine in dextrose injection, USP) 15 mg/2 mL (7.5 mg/mL) Glass Ampoule |
| 00409-1623-01 | Butorphanol Tartrate Injection, USP, CIV 1 mg/mL Single Dose Glass Fliptop Vial |
| 00409-1626-01 | Butorphanol Tartrate Injection, USP, CIV 2 mg/mL Single Dose Glass Fliptop Vial |
| 00409-1626-02 | Butorphanol Tartrate Injection, USP, CIV 4 mg/2 mL (2 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1631-10 | Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) ANSYR™ Plastic Syringe |
| 00409-4928-34 | Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") |
| 00409-1775-10 | Dextrose Injection 25%, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR™ Plastic Syringe |
| 00409-7517-16 | Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) ANSYR™ II Plastic Syringe (side/side) |
| 00409-4902-34 | Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (18 G x 1 1/2") |
| 00409-6648-02 | Dextrose Injection 50%, USP 25 g/50 mL (500 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-2346-32 | Dobutamine in 5% Dextrose Injection, USP 250 mg/250 mL (1 mg/mL) Flexible Container |
| 00409-2347-32 | Dobutamine in 5% Dextrose Injection, USP 500 mg/250 mL (2 mg/mL) Flexible Container |
| 00409-3724-32 | Dobutamine in 5% Dextrose Injection, USP 1,000 mg/250 mL (4 mg/mL) Flexible Container |
| 00409-7809-22 | Dopamine Hydrochloride in 5% Dextrose Injection, USP 400 mg/250 mL (1,600 mcg/mL) Flexible Container |
| 00409-7810-22 | Dopamine Hydrochloride in 5% Dextrose Injection, USP 800 mg/250 mL (3,200 mcg/mL) Flexible Container |
| 00409-4933-01 | Epinephrine Injection, USP 1 mg/10 mL (0.1 mg/mL) ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle |
| 00409-9094-22 | Fentanyl Citrate Injection, USP, CII 100 mcg/2 mL (50 mcg/mL) Single Dose Glass Fliptop Vial |
| 00409-9093-35 | Fentanyl Citrate Injection, USP, CII 250 mcg/5 mL (50 mcg/mL) Glass Ampoule |
| 00409-7651-62 | Heparin Sodium in 0.45% Sodium Chloride Injection, 12,500 USP Units/250 mL (50 USP Units/mL) Flexible Container |
| 00409-7650-62 | Heparin Sodium in 0.45% Sodium Chloride Injection, 25,000 USP Units/250 mL (100 USP Units/mL) Flexible Container |

| | |
|---------------|--|
| 00409-3177-01 | Lidocaine Hydrochloride and Epinephrine Injection 0.5%, USP (Lidocaine and Epinephrine 1:200,000) 250 mg/50 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3178-01 | Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 200 mg/20 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3178-02 | Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 300 mg/30 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3178-03 | Lidocaine Hydrochloride and Epinephrine Injection 1%, USP (Lidocaine and Epinephrine 1:100,000) 500 mg/50 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3181-01 | Lidocaine Hydrochloride and Epinephrine Injection 1.5%, USP (Lidocaine and Epinephrine 1:200,000) 450 mg/30 mL (15 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1209-01 | Lidocaine Hydrochloride 1.5% and Epinephrine Injection, USP (Lidocaine and Epinephrine 1:200,000) 75 mg/5 mL (15 mg/mL) Glass Ampoule |
| 00409-3182-03 | Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 1,000 mg/50 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3182-01 | Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 400 mg/20 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3182-02 | Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:100,000) 600 mg/30 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-3183-01 | Lidocaine Hydrochloride and Epinephrine Injection 2%, USP (Lidocaine and Epinephrine 1:200,000) 400 mg/20 mL (20 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-9137-05 | Lidocaine Hydrochloride Injection 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) ANSYR™ Plastic Syringe |
| 00409-1323-05 | Lidocaine Hydrochloride Injection 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) ANSYR™ Plastic Syringe |
| 00409-4903-34 | Lidocaine Hydrochloride Injection 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") |
| 00409-4277-02 | Lidocaine Hydrochloride Injection 2%, USP 1,000 mg/50 mL (20 mg/mL) Multiple Dose Plastic Fliptop Vial |
| 00409-4883-01 | Linezolid Injection in 0.9% Sodium Chloride 600 mg/300 mL (2 mg/mL) VisIV™ Flexible Container |
| 00409-6729-03 | Magnesium Sulfate in Water for Injection 20 g/500 mL (40 mg/mL) Flexible Container |
| 00409-4031-01 | Mannitol Injection, USP 12.5 g/50 mL Single Dose Glass Fliptop Vial (25% concentration) |
| 00409-2305-17 | Midazolam Injection, USP CIV 2 mg/2 mL (1 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-2308-02 | Midazolam Injection, USP CIV 10 mg/2 mL (5 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1134-03 | Morphine Sulfate Injection, USP, CII (Preservative-Free and contains an antioxidant) 1,000 mg/20 mL (50 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1134-05 | Morphine Sulfate Injection, USP, CII (Preservative-Free and contains an antioxidant) 2,500 mg/50 mL (50 mg/mL) Single Dose Glass Fliptop Vial |
| 00409-1465-01 | Nalbuphine Hydrochloride Injection 20 mg/mL Glass Ampoule |
| 00409-1215-01 | Naloxone Hydrochloride Injection, USP 0.4 mg/mL Single Dose Glass Fliptop Vial |
| 00409-8183-01 | Potassium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial |
| 00409-6651-06 | Potassium Chloride for Injection Concentrate, USP 20 mEq/10 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial |
| 00409-7295-01 | Potassium Phosphates Injection, USP, 45 mM P/15 mL (3 mM P/mL) Single Dose Glass Fliptop Vial |
| 00409-6629-02 | Quelicin™ (succinylcholine chloride injection, USP) 200 mg/10 mL (20 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-9558-05 | Rocuronium Bromide Injection 50 mg/5 mL (10 mg/mL) Multiple Dose Glass Fliptop Vial |
| 00409-7299-73 | Sodium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial |

| | |
|---------------|--|
| 00409-3299-06 | Sodium Acetate Injection, USP 200 mEq/100 mL (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial |
| 00409-5534-14 | 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL) ABBOJECT® Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle |
| 00409-5555-02 | 4.2% Sodium Bicarbonate Injection, USP 5 mL Fliptop Vial |
| 00409-4916-14 | 7.5% Sodium Bicarbonate Injection, USP 44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 18-Gauge protected needle |
| 00409-6637-14 | 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) LifeShield® ABBOJECT® Glass Syringe Male Luer Lock Adapter and 18-Gauge protected needle |
| 00409-1141-02 | 23.4% Sodium Chloride Injection, USP 400 mEq/100 mL (4 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial |
| 00409-7391-72 | Sodium Phosphates Injection, USP 45 mMol/15 mL (3 mMol P/mL) Single Dose Plastic Fliptop Vial |
| 00409-5816-11 | Sterile Empty Vial 10 mL Glass Bottle |
| 00409-5816-31 | Sterile Empty Vial 30 mL Glass Bottle |
| 00409-9158-01 | Vitamin K1 (phytonadione injectable emulsion, USP) 10 mg/mL Glass Ampoule |